Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ralph M Fritsch"'
Autor:
Saskia Hussung, Dilara Akhoundova, Julian Hipp, Marie Follo, Rhena F. U. Klar, Ulrike Philipp, Florian Scherer, Nikolas von Bubnoff, Justus Duyster, Melanie Boerries, Uwe Wittel, Ralph M. Fritsch
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal analysis of mutated cell
Externí odkaz:
https://doaj.org/article/df151022f76648449f2bf707053b3b13
Precision Oncology for Hepato-Pancreato-Biliary (HPB) Cancers State of the Art and Future Directions
Publikováno v:
healthbook TIMES. Oncology Hematology, Vol 5, Iss 3 (2020)
The revolution of precision medicine is rapidly changing the way we diagnose and treat cancer. The wide availability of comprehensive molecular profiling has led to the rapid accumulation of a wealth of molecular data, and no medical oncologist can e
Externí odkaz:
https://doaj.org/article/42bebf32cce44bbf957b83b5a26682af
Autor:
Dilara Akhoundova, Saskia Hussung, Smruthy Sivakumar, Antonia Töpfer, Markus Rechsteiner, Abdullah Kahraman, Fabian Arnold, Florian Angst, Christian Britschgi, Martin Zoche, Holger Moch, Achim Weber, Ethan Sokol, Ralph M. Fritsch
Publikováno v:
Akhoundova, Dilara; Hussung, Saskia; Sivakumar, Smruthy; Töpfer, Antonia; Rechsteiner, Markus; Kahraman, Abdullah; Arnold, Fabian; Angst, Florian; Britschgi, Christian; Zoche, Martin; Moch, Holger; Weber, Achim; Sokol, Ethan; Fritsch, Ralph M (2022). ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer. International journal of cancer, 151(12), pp. 2161-2171. Wiley-Blackwell 10.1002/ijc.34257
c-Ros oncogene 1, receptor tyrosine kinase (ROS1) genomic rearrangements have been reported previously in rare cases of colorectal cancer (CRC), yet little is known about the frequency, molecular characteristics, and therapeutic vulnerabilities of RO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7de68fab5acf34d23136a348c94a31c
https://boris.unibe.ch/174912/1/Intl_Journal_of_Cancer_-_2022_-_Akhoundova_-_ROS1_genomic_rearrangements_are_rare_actionable_drivers_in_microsatellite.pdf
https://boris.unibe.ch/174912/1/Intl_Journal_of_Cancer_-_2022_-_Akhoundova_-_ROS1_genomic_rearrangements_are_rare_actionable_drivers_in_microsatellite.pdf
Autor:
Julius Wehrle, Ulrike Philipp, Martina Jolic, Marie Follo, Saskia Hussung, Silvia Waldeck, Max Deuter, Michael Rassner, Jan Braune, Justyna Rawluk, Christine Greil, Cornelius F. Waller, Heiko Becker, Jesús Duque-Afonso, Anna L. Illert, Ralph M. Fritsch, Frank Meiss, Justus Duyster, Nikolas von Bubnoff, Florian Scherer
Publikováno v:
Diagnostics, Vol 10, Iss 8, p 550 (2020)
Background: Circulating tumor DNA (ctDNA) in the blood plasma of cancer patients is an emerging biomarker used across oncology, facilitating noninvasive disease monitoring and genetic profiling at various disease milestones. Digital droplet PCR (ddPC
Externí odkaz:
https://doaj.org/article/e63030888c5d4ece9ce2c4dc54ca2dd8
Autor:
Lukas M. Braun, Simon Lagies, Rhena F. U. Klar, Saskia Hussung, Ralph M. Fritsch, Bernd Kammerer, Uwe A. Wittel
Publikováno v:
Cancers, Vol 12, Iss 6, p 1440 (2020)
Pancreatic ductal adenocarcinoma (PDAC) is associated with high mortality and will become the second most common cause of cancer-associated mortality by 2030. The poor prognosis arises from a lack of sensitive biomarkers, limited therapeutic options,
Externí odkaz:
https://doaj.org/article/f5a87ba1523d456685bc78484bc7d65d
Autor:
Sebastian Stintzing, Eyck von der Heyde, Jan Wierecky, Dieter Bürkle, Helmut Forstbauer, Gerdt Hübner, Burkhard Schmidt, Jan Schroeder, Andrea Distelrath, Marion Flum, Frank Reichenbach, Dirk Arnold, Ralph M Fritsch, Armin Gerger, Susanna Hegewisch-Becker, Arndt Vogel, Anna Dorothea Wagner, Thomas Winder, Dieter Koeberle, Gerald W. Prager
Publikováno v:
Journal of Clinical Oncology. 41:34-34
34 Background: BRAF V600E-mutant metastatic colorectal cancer (mCRC) is associated with a poor prognosis and limited clinical data. Based on results from the BEACON CRC trial, targeted treatment with encorafenib plus cetuximab (E+C) is available as a
Autor:
Sebastian Stintzing, Gerdt Hübner, Jan Schröder, Helmut Forstbauer, Jens Kisro, Manfred Welslau, Harald Müller-Huesmann, Dieter Bürkle, Beate Krammer-Steiner, Eyck von der Heyde, Frank Reichenbach, Dirk Arnold, Ralph M Fritsch, Armin Gerger, Susanna Hegewisch-Becker, Arndt Vogel, Anna Dorothea Wagner, Thomas Winder, Dieter Koeberle, Gerald Prager
Publikováno v:
Journal of Clinical Oncology. 40:e15584-e15584
e15584 Background: BRAF V600E-mutant metastatic colorectal cancer (mCRC) is characterized by a poor prognosis and limited clinical data. Based on results from the phase 3 BEACON CRC trial, targeted treatment with encorafenib plus cetuximab (E+C) repr
Autor:
Saskia Hussung, Dilara Akhoundova, Smruthy Sivakumar, Abdullah Kahraman, Martin Zoche, Markus Rechsteiner, Florian Angst, Christian Britschgi, Antonia Töpfer, Holger Moch, Achim Weber, Ethan Sokol, Ralph M Fritsch
Publikováno v:
Journal of Clinical Oncology. 40:160-160
160 Background: c-Ros oncogene 1, receptor tyrosine kinase ( ROS1) rearrangements have been reported in colorectal cancer (CRC), but little is known about the molecular and clinical features of ROS1-driven CRC and the response to ROS1-targeted treatm